We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Higher Estrogen Levels Linked to Severe Disease in Scleroderma

By LabMedica International staff writers
Posted on 19 Jun 2019
Systemic sclerosis (SSc) is an autoimmune, connective tissue disease of unknown etiology characterized by immune system dysregulation and excessive extracellular matrix (ECM) synthesis. More...
As in most autoimmune diseases, there is a female predominance in SSc with a female to male ratio of 3:1, which increases to 9:1 during childbearing years.

Male patients have more severe disease compared to women. Men have more severe interstitial lung disease (ILD), which is currently the leading cause of death in SSc patients and significantly reduces survival. Scleroderma is a connective tissue disease that hardens the skin and scars the organs. Older men with scleroderma had higher estrogen levels than healthy older men or postmenopausal women with scleroderma.

A team of scientists working with the University of South Carolina (Charleston, SC, USA) tested estradiol and scleroderma autoantibody levels in banked samples from 83 men aged 50 years and older with diffuse cutaneous systemic sclerosis, a type of scleroderma. They also tested samples from 37 healthy men of a similar age. They then used a variety of statistical approaches and the careful clinical annotations accompanying each sample to determine whether estradiol levels were linked to any of the clinical traits of scleroderma.

Serum samples were collected at the time of the first visit and stored at − 80 °C. Serum samples were thawed on ice prior to estradiol (E2) measurement. Each undiluted serum sample was measured in duplicate using an enzyme-linked immunosorbent assay (ELISA) (Calbiotech, Spring Valley, CA, USA) that has been previously validated against mass spectrometry At the time of enrollment, the SSc patients’ autoantibody profiles were determined from serum samples collected and analyzed by the Scleroderma Center Research laboratory. The team tested for antibodies targeting RNA polymerase III (POL3), Scl-70, U1RNP, U11/U12 RNP, and centromere.

The scientist reported that male patients with diffuse cutaneous scleroderma had significantly higher levels of estradiol (mean, 30.6 pg/mL) than both healthy men (mean, 12.9 pg/mL) and postmenopausal women with the disease (24.2 pg/mL). Those with higher estradiol levels (mean, 43.7 pg/mL) had significantly more heart involvement than those with lower levels (29.4 pg/mL). Finally, for patients with the Scl-70 autoantibody, increasing levels of estradiol in the serum was associated with a significantly greater risk of death.

The authors concluded that male diffuse cutaneous SSc (dcSSc) patients older than 50 years have significantly elevated serum E2 levels compared to healthy controls and post-menopausal females with dcSSc. Higher serum E2 levels are associated with cardiac involvement, decreased survival, and increased risk of death in Scl-70-positive patients. These initial findings provide insights into the potential impact of elevated E2 levels in dcSSc and may explain, at least in part, the increased mortality in older male patients with dcSSc. The study was published originally published on April 2, 2019, in the journal Arthritis Research & Therapy.

Related Links:
University of South Carolina
Calbiotech



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
New
Hemoglobin Stool Test
CerTest FOB 50 + 200 One Step Combo Card Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.